NASDAQ:KPRX
Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc.'s revenue fell 100.0% in fiscal 2025 to $0. Free cash flow was −$10.1M, and the diluted share count fell 0.5%.Summary generated from Kiora Pharmaceuticals Inc.'s SEC filings. Latest annual report filed Mar 25, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$0
Revenue growth−100.0%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−51.7%
Debt / equityn/a
Free cash flow−$10.1M
FCF marginn/a
Share count change−0.5%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | n/a | 0 | 16 | 0 |
| Operating income | −14 | −12 | −13 | 5 | −13 |
| Net income | −14 | −14 | −13 | 4 | −11 |
| Free cash flow | −11 | −10 | −10 | 9 | −10 |
Recent filings
- 4Insider transaction report
Sep 17, 2026 - 8-KDirector or officer change
Sep 8, 2026 - 8-KEntry into a material agreement
Aug 19, 2026 - 8-KResults of operations and financial condition
Aug 7, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 7, 2026 - 4Insider transaction report
Jul 2, 2026 - 8-KRegulation FD disclosure
Jun 18, 2026 - 8-KDirector or officer change
Jun 11, 2026